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Preface	  Genetic	  driver	  events	  in	  cancer	  activate	  signaling	  pathways	  that	  alter	  cell	  metabolism.	  	  Clinical	  evidence	  has	  linked	  metabolism	  with	  cancer	  outcomes.	  	  Together,	  this	  has	  raised	  interest	  in	  targeting	  metabolic	  enzymes	  for	  cancer	  therapy,	  but	  also	  concerns	  that	  these	  therapies	  would	  have	  unacceptable	  effects	  on	  normal	  cells.	  	  However,	  some	  of	  the	  first	  cancer	  therapies	  target	  the	  specific	  metabolic	  needs	  of	  cancer	  cells	  and	  remain	  effective	  agents	  used	  in	  the	  clinic	  today.	  	  Research	  to	  understand	  how	  changes	  in	  cell	  metabolism	  promote	  tumor	  growth	  has	  accelerated	  in	  recent	  years.	  	  This	  has	  refocused	  efforts	  on	  targeting	  metabolic	  dependencies	  of	  cancer	  cells,	  an	  approach	  with	  the	  potential	  to	  have	  a	  major	  impact	  on	  patient	  care.	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Proliferating	  cancer	  cells	  exhibit	  significantly	  different	  metabolic	  requirements	  than	  most	  normal	  differentiated	  cells1.	  	  For	  example,	  in	  order	  to	  support	  their	  high	  rates	  of	  proliferation,	  cancer	  cells	  consume	  additional	  nutrients	  and	  divert	  those	  nutrients	  into	  macromolecular	  synthesis	  pathways	  (Figure	  1a).	  	  Metabolic	  pathways	  must	  therefore	  be	  rewired	  in	  such	  a	  way	  that	  balances	  biosynthetic	  processes	  with	  sufficient	  ATP	  production	  to	  support	  growth	  and	  survival.	  	  Because	  all	  cancer	  cells	  are	  dependent	  on	  this	  change	  in	  metabolism,	  these	  altered	  pathways	  represent	  attractive	  therapeutic	  targets2,	  3.	  	  However,	  because	  normal	  proliferating	  cells	  have	  the	  same	  metabolic	  requirements,	  finding	  a	  therapeutic	  window	  between	  proliferating	  cancer	  cells	  and	  proliferating	  normal	  cells	  remains	  a	  major	  challenge	  to	  developing	  successful	  cancer	  therapies	  targeting	  metabolic	  pathways.	  	  	   Many	  cancer	  cells,	  unlike	  their	  normal	  counterparts,	  metabolize	  glucose	  by	  aerobic	  glycolysis1,	  4,	  5.	  	  This	  phenomenon,	  known	  as	  the	  Warburg	  effect,	  is	  characterized	  by	  increased	  glycolysis	  and	  high	  lactate	  production	  regardless	  of	  oxygen	  availability.	  	  Aerobic	  glycolysis	  is	  often	  accompanied	  by	  increased	  glucose	  uptake,	  and	  this	  phenomenon	  may	  be	  visualized	  in	  patient	  tumors	  using	  18F-­‐deoxyglucose	  positron	  emission	  tomography	  (FDG-­‐PET)	  scanning.	  	  FDG-­‐PET	  scanning	  is	  used	  clinically	  as	  a	  staging	  tool	  for	  diverse	  cancer	  types,	  and	  experimental	  PET	  tracers	  can	  distinguish	  cancer	  from	  normal	  cells	  based	  on	  other	  aspects	  of	  cancer	  metabolism6.	  	  Differential	  uptake	  of	  11C-­‐choline,	  11C-­‐acetate,	  11C	  –methionine,	  and	  18F-­‐labeled	  amino	  acid	  analogs	  has	  also	  been	  demonstrated	  in	  some	  human	  cancers6,	  7.	  	  Variable	  uptake	  of	  these	  molecules	  as	  well	  as	  FDG,	  and	  variable	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secretion	  of	  lactate,	  are	  all	  observed	  in	  human	  cancers	  even	  among	  tumors	  arising	  from	  the	  same	  tissue6-­‐9.	  	  Why	  some	  cancers	  exhibit	  increased	  labeling	  with	  these	  tracers	  is	  not	  understood,	  however	  these	  findings	  suggest	  that	  tumors	  exhibit	  heterogeneous	  metabolic	  alterations	  that	  extend	  beyond	  the	  Warburg	  effect	  (Figure	  1b).	  	  Nevertheless,	  all	  cancer	  cells	  must	  ultimately	  direct	  available	  nutrients	  into	  the	  synthesis	  of	  new	  biomass	  while	  maintaining	  adequate	  ATP	  levels	  for	  cell	  survival.	  	  Therefore,	  it	  is	  likely	  these	  phenotypic	  differences	  are	  manifestations	  of	  various	  metabolic	  solutions	  individual	  cancers	  use	  to	  support	  proliferation.	  	   At	  least	  some	  of	  the	  metabolic	  heterogeneity	  observed	  in	  tumors	  is	  influenced	  by	  the	  microenvironment5.	  	  Gradients	  of	  nutrients,	  oxygen,	  and	  pH	  can	  result	  from	  abnormal	  tumor	  vasculature.	  	  Glucose,	  amino	  acids	  and	  lipids	  provide	  the	  substrates	  available	  to	  supply	  metabolic	  pathways,	  and	  thus	  metabolism	  will	  change	  based	  on	  the	  concentrations	  of	  these	  metabolites	  available	  to	  cells.	  	  In	  addition,	  cells	  have	  signaling	  mechanisms	  linked	  to	  growth	  control	  pathways	  that	  sense	  conditions	  such	  as	  amino	  acid	  availability	  and	  oxygen	  levels	  and	  that	  influence	  metabolism5,	  10-­‐12.	  	  	  Genetic	  alterations	  associated	  with	  cancer	  often	  occur	  in	  these	  same	  signaling	  pathways,	  suggesting	  that	  both	  environmental	  and	  genetic	  factors	  influence	  the	  metabolic	  heterogeneity	  present	  across	  tumors5.	  	  Despite	  a	  deep	  understanding	  of	  metabolic	  regulation	  built	  upon	  almost	  a	  century	  of	  biochemistry	  research,	  our	  knowledge	  of	  how	  pathways	  are	  regulated	  to	  facilitate	  cell	  proliferation	  is	  incomplete13.	  	  Success	  in	  targeting	  cancer	  metabolism	  will	  emerge	  from	  further	  understanding	  of	  precisely	  how	  cells	  regulate	  nutrient	  flux	  into	  pathways	  required	  for	  biosynthesis	  in	  specific	  genetic	  contexts.	  	  Understanding	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tumor	  cell	  metabolism	  requires	  the	  use	  of	  methods	  to	  assess	  metabolite	  flux	  and	  pathway	  regulation	  that	  are	  not	  often	  employed	  in	  cancer	  drug	  discovery.	  	  However,	  akin	  to	  how	  antibiotics	  target	  the	  biosynthetic	  processes	  unique	  to	  microorganisms,	  selective	  targeting	  of	  the	  biosynthetic	  processes	  of	  cancer	  cells	  holds	  tremendous	  promise	  as	  a	  strategy	  to	  improve	  cancer	  therapy.	  	  Here,	  we	  review	  existing	  evidence	  supporting	  the	  therapeutic	  potential	  of	  targeting	  the	  metabolic	  adaptations	  that	  are	  characteristic	  of	  cancer	  cells,	  discuss	  the	  associated	  challenges	  and	  limitations	  of	  this	  as	  an	  anticancer	  strategy,	  and	  outline	  a	  framework	  to	  consider	  new	  targets	  in	  metabolism.	  	  We	  also	  discuss	  emerging	  evidence	  involving	  specific	  metabolic	  enzyme	  targets,	  and	  how	  they	  might	  be	  used	  to	  limit	  cell	  proliferation.	  	  To	  date	  only	  a	  handful	  of	  molecules	  targeting	  metabolic	  pathways	  have	  been	  tested	  as	  cancer	  therapy.	  	  However	  a	  growing	  body	  of	  evidence	  supports	  the	  notion	  that	  altered	  metabolism	  is	  a	  key	  consequence	  of	  important	  genetic	  drivers	  of	  cancer,	  inciting	  renewed	  interest	  in	  exploring	  metabolic	  enzymes	  as	  therapeutic	  targets.	  	  
Why	  target	  cancer	  cell	  metabolism?	  
Metabolism	  may	  influence	  cancer	  initiation	  and	  progression	  Clinical	  studies	  have	  linked	  altered	  whole-­‐body	  metabolism	  to	  cancer	  development,	  progression,	  and	  poor	  treatment	  outcomes.	  	  Indeed,	  obesity,	  hyperglycemia,	  and	  insulin	  resistance	  are	  all	  associated	  with	  an	  increased	  risk	  of	  developing	  cancer	  and	  worse	  outcomes	  among	  patients	  with	  cancer14-­‐18.	  	  However,	  how	  such	  changes	  in	  organismal	  metabolism	  influence	  metabolism	  at	  the	  cellular	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level	  to	  promote	  cancer	  is	  controversial.	  	  Increased	  circulating	  insulin	  and	  insulin-­‐like	  growth	  factor	  levels	  have	  been	  linked	  with	  cancer	  progression,	  suggesting	  obesity	  and	  insulin	  resistance	  promote	  cancer	  at	  least	  in	  part	  by	  activating	  signaling	  pathways	  that	  drive	  cell	  growth15.	  	  These	  same	  signaling	  pathways	  also	  drive	  nutrient	  uptake	  into	  cells	  and	  regulate	  enzymes	  in	  glycolysis,	  implying	  that	  hormonal	  changes	  can	  have	  important	  indirect	  effects	  on	  cancer	  cell	  metabolism16.	  	  Furthermore,	  elevated	  glucose	  levels	  alone	  may	  promote	  increased	  glucose	  uptake	  in	  some	  cells,	  and	  lower	  circulating	  glucose	  levels	  are	  associated	  with	  better	  cancer	  treatment	  outcomes19-­‐22.	  	  As	  a	  result,	  anti-­‐diabetic	  drugs	  are	  being	  explored	  for	  anti-­‐tumor	  activity,	  and	  retrospective	  clinical	  studies	  have	  shown	  a	  reduction	  in	  cancer-­‐related	  mortality	  for	  diabetic	  patients	  taking	  metformin23,	  24.	  	  This	  effect	  appears	  to	  be	  independent	  of	  blood	  glucose,	  as	  diabetic	  patients	  who	  control	  glucose	  levels	  by	  other	  means	  do	  not	  derive	  the	  same	  benefit	  as	  individuals	  taking	  metformin24.	  	  Metformin	  is	  widely	  used	  for	  the	  treatment	  of	  type	  II	  diabetes	  and	  acts	  by	  inhibiting	  mitochondrial	  complex	  I	  in	  the	  liver	  to	  interfere	  with	  ATP	  production25,	  26.	  	  This	  causes	  energy	  stress,	  increased	  AMP-­‐activated	  protein	  kinase	  (AMPK)	  activity,	  and	  inhibition	  of	  gluconeogenesis	  resulting	  in	  lower	  blood	  glucose	  levels	  and	  improved	  insulin	  sensitivity27.	  	  Because	  metformin	  lowers	  insulin	  levels,	  it	  is	  controversial	  whether	  metformin	  benefits	  cancer	  patients	  by	  directly	  acting	  on	  the	  tumor,	  or	  by	  indirectly	  decreasing	  levels	  of	  insulin-­‐related	  growth	  factors.	  	  Other	  anti-­‐diabetic	  therapies	  that	  act	  by	  raising	  insulin	  levels	  may	  therefore	  in	  fact	  lead	  to	  worse	  outcomes.	  	  Dietary	  restriction,	  which	  has	  been	  known	  to	  prolong	  survival	  in	  cancer	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models,	  has	  no	  effect	  on	  tumors	  that	  proliferate	  in	  the	  absence	  of	  insulin-­‐like	  growth	  factor	  signaling28.	  	  These	  findings	  are	  consistent	  with	  metformin	  providing	  an	  indirect	  benefit	  to	  patients	  with	  high	  circulating	  insulin-­‐related	  growth	  factors.	  	  However,	  high	  doses	  of	  metformin	  are	  toxic	  to	  cancer	  stem	  cells29,	  and	  women	  taking	  metformin	  have	  an	  increased	  tumor	  response	  to	  neoadjuvant	  chemotherapy	  for	  breast	  cancer	  that	  may	  extend	  to	  non-­‐diabetics30.	  	  LKB1,	  a	  kinase	  important	  for	  AMPK	  activation	  in	  response	  to	  metformin27,	  is	  frequently	  lost	  in	  human	  cancers5.	  	  Thus,	  metformin	  use	  to	  induce	  energy	  stress	  may	  be	  particularly	  beneficial	  for	  treating	  LKB1-­‐deficient	  tumors	  because	  these	  cells	  are	  unable	  to	  activate	  AMPK	  and	  cope	  with	  this	  stress31.	  	  Planned	  adjuvant	  trials	  of	  metformin	  in	  breast	  cancer	  patients	  will	  provide	  additional	  insight.	  	  It	  is	  also	  possible	  that	  metformin	  could	  be	  used	  as	  chemoprevention	  in	  patients	  with	  a	  high	  risk	  of	  developing	  cancer32,	  33,	  although	  the	  best	  strategy	  to	  identify	  individuals	  to	  include	  in	  such	  trials	  has	  yet	  to	  be	  determined34.	  Regardless	  of	  whether	  the	  benefit	  observed	  with	  metformin	  involves	  a	  direct	  effect	  on	  cell	  metabolism,	  blocking	  the	  signals	  that	  link	  whole	  body	  metabolism	  to	  cellular	  metabolism	  presents	  therapeutic	  opportunities.	  	  Antibodies	  and	  small	  molecule	  kinase	  inhibitors	  directed	  against	  the	  insulin-­‐like	  growth	  factor	  receptor	  (IGFR)	  have	  been	  well	  tolerated	  by	  patients35.	  	  Early	  studies	  with	  these	  agents	  have	  focused	  on	  sarcomas	  based	  on	  preclinical	  evidence	  suggesting	  these	  tumors	  are	  dependent	  on	  IGFR	  signaling.	  	  In	  fact,	  some	  rare	  sarcoma	  patients	  develop	  tumor-­‐associated	  hypoglycemia	  related	  to	  increased	  production	  of	  an	  IGF	  isoform,	  and	  dramatic	  anecdotal	  responses	  have	  been	  reported	  in	  these	  individuals36.	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Unfortunately,	  overall	  these	  agents	  have	  demonstrated	  limited	  efficacy	  in	  trials	  suggesting	  that	  their	  clinical	  utility	  has	  yet	  to	  be	  determined35.	  	  Further	  efforts	  to	  identify	  those	  tumors	  with	  altered	  metabolism	  dependent	  on	  IGFR-­‐signaling	  may	  allow	  selection	  of	  patients	  to	  benefit	  from	  these	  therapies.	  	  Insulin-­‐like	  growth	  factors	  are	  thought	  to	  increase	  tumor	  growth	  by	  activating	  the	  phosphoinositide-­‐3-­‐kinase	  (PI3K)	  signal	  transduction	  pathway,	  which	  influences	  metabolic	  pathways	  as	  one	  of	  many	  downstream	  effectors	  of	  this	  signaling	  pathway4,	  37.	  	  In	  addition,	  mTOR	  (mammalian	  target	  of	  rapamycin),	  a	  major	  effector	  downstream	  of	  PI3K	  is	  regulated	  by	  nutrient	  availability12.	  	  mTOR	  activation	  stimulates	  a	  metabolic	  program	  to	  promote	  cell	  growth38,	  mTOR	  inhibitors	  are	  increasingly	  used	  in	  the	  clinic	  to	  treat	  various	  cancers,	  and	  many	  compounds	  targeting	  the	  PI3K	  pathway	  are	  in	  clinical	  development39,	  40.	  	  A	  better	  understanding	  of	  how	  these	  drugs	  affect	  tumor	  metabolism	  may	  define	  mechanisms	  of	  resistance	  to	  these	  agents	  or	  identify	  synergistic	  targets	  in	  metabolism	  that	  might	  convert	  mTOR	  inhibitors	  from	  cytostatic	  to	  cytotoxic	  agents	  and	  increase	  their	  efficacy	  in	  patients.	  	  
Targeting	  metabolism	  could	  improve	  existing	  approaches	  Many	  genetic	  alterations	  known	  to	  promote	  cancer	  lead	  to	  a	  single	  converging	  metabolic	  phenotype	  characterized	  by	  enhanced	  cell	  autonomous	  nutrient	  uptake	  and	  metabolic	  pathway	  reorganization	  to	  support	  biosynthesis4,	  5,	  41.	  	  Growth	  signaling	  pathways	  activated	  in	  cancer	  promote	  these	  metabolic	  changes,	  and	  compounds	  that	  target	  signal	  transduction	  pathways	  are	  available	  in	  the	  clinic.	  	  Despite	  significant	  success	  with	  these	  agents	  in	  select	  cancers42,	  for	  many	  common	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malignancies	  challenges	  remain	  to	  identify	  which	  patients	  are	  likely	  to	  respond	  to	  these	  drugs.	  	  Interestingly,	  a	  decrease	  in	  glucose	  uptake	  as	  measured	  by	  FDG-­‐PET	  scan	  has	  been	  predictive	  of	  response	  to	  compounds	  targeting	  the	  PI3K	  pathway	  in	  animal	  models43	  and	  kinase	  inhibitors	  in	  patients44.	  	  	  These	  findings	  support	  the	  hypothesis	  that	  a	  major	  metabolic	  consequence	  of	  inappropriate	  PI3K	  or	  tyrosine	  kinase	  activation	  is	  promoting	  nutrient	  uptake.	  	  There	  is	  also	  evidence	  that	  increased	  nutrient	  uptake	  is	  a	  critical	  effect	  of	  oncogenic	  RAS	  mutations45,	  and	  decreased	  nutrient	  uptake	  can	  predict	  therapy	  response	  in	  KRAS-­‐driven	  lung	  cancer43.	  	  This	  underscores	  the	  potential	  value	  of	  FDG-­‐PET	  scanning	  as	  an	  early	  predictor	  of	  response	  to	  molecules	  targeting	  signaling	  pathways.	  Despite	  creative	  approaches,	  effective	  agents	  targeting	  many	  of	  the	  common	  driver	  mutations	  in	  cancer	  are	  not	  available.	  	  For	  instance,	  mutations	  in	  RAS	  or	  inappropriate	  expression	  of	  MYC	  are	  frequent	  events	  in	  human	  cancer,	  yet	  no	  specific	  therapies	  exist	  to	  treat	  cancers	  based	  on	  either	  genetic	  event,	  and	  many	  
RAS-­‐driven	  cancers	  are	  refractory	  to	  existing	  therapies46,	  47.	  	  Enzymes	  in	  metabolism	  appear	  to	  be	  key	  effectors	  of	  both	  pathways.	  	  	  RAS	  mutant	  cells	  are	  dependent	  on	  sufficient	  glucose	  uptake45,	  and	  MYC-­‐dependent	  cells	  have	  a	  particular	  reliance	  on	  glutamine	  metabolism48-­‐50.	  	  In	  preclinical	  models,	  targeting	  metabolic	  enzymes	  has	  been	  effective	  for	  treating	  KRAS-­‐mutant45,	  51	  and	  MYC-­‐dependent	  tumors	  52,	  53.	  	  For	  instance,	  small	  molecule	  inhibitors	  that	  disrupt	  glucose	  metabolism	  can	  decrease	  growth	  of	  xenograft	  tumors	  derived	  from	  cells	  driven	  by	  these	  oncogenes45,	  51,	  53.	  	  	  This	  suggests	  that	  targeting	  metabolism	  as	  an	  effector	  of	  signal	  transduction	  pathways	  required	  for	  growth	  might	  be	  a	  way	  to	  attack	  cancers	  driven	  by	  genetic	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alterations	  that	  cannot	  be	  targeted	  directly.	  	  Furthermore,	  because	  kinase	  inhibitor	  therapies	  can	  result	  in	  decreased	  glucose	  uptake1,	  43,	  compounds	  that	  further	  impair	  glucose	  metabolism	  may	  be	  synergistic	  with	  these	  approaches.	  	  Cytotoxic	  therapies	  also	  compromise	  glucose	  metabolism54,	  and	  targeting	  metabolism	  may	  sensitize	  cancers	  to	  these	  drugs	  as	  well.	  	  
Metabolism	  is	  a	  proven	  target	  of	  successful	  therapies.	  Given	  that	  all	  cancer	  cells	  rely	  on	  changes	  in	  metabolism	  to	  support	  their	  growth	  and	  survival,	  targeting	  metabolism	  has	  the	  potential	  to	  impact	  cancers	  arising	  from	  many	  different	  tissues2.	  	  	  In	  fact,	  the	  possibility	  that	  agents	  targeting	  cell	  metabolism	  could	  be	  effective	  across	  diverse	  cancer	  types	  has	  historical	  precedent.	  	  For	  example,	  the	  development	  of	  anti-­‐folates	  took	  place	  prior	  to	  an	  understanding	  of	  how	  folic	  acid	  contributes	  to	  a	  metabolic	  cycle	  that	  allows	  single	  carbon	  transfer	  reactions	  (Box	  1).	  	  These	  reactions	  are	  critical	  for	  the	  generation	  of	  nucleic	  acids	  (Figure	  2),	  and	  the	  success	  of	  anti-­‐folates	  led	  to	  the	  study	  of	  other	  metabolite	  analogues	  as	  potential	  anti-­‐cancer	  agents	  that	  disrupt	  nucleotide	  synthesis55,	  56.	  	  Today,	  the	  anti-­‐metabolite	  class	  of	  nucleoside	  analogs	  including	  5-­‐flurouracil,	  gemcitibine,	  and	  fludarabine,	  along	  with	  hydroxyurea	  and	  a	  newer	  generation	  of	  antifolates	  (e.g.	  pemetrexed)	  are	  widely	  used	  in	  the	  treatment	  of	  diverse	  human	  tumors.	  	  While	  these	  drugs	  are	  not	  considered	  by	  most	  to	  be	  “targeted	  therapies,”	  they	  have	  clear	  targets	  in	  metabolism	  such	  as	  dihydrofolate	  reductase	  and	  thymidylate	  synthase	  (Figure	  2,	  Table	  1),	  and	  remain	  effective	  therapies	  for	  many	  human	  cancers.	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The	  use	  of	  the	  enzyme	  L-­‐asparaginase	  to	  treat	  acute	  lymphoblastic	  leukemia	  (ALL)	  and	  related	  lymphomas	  is	  another	  example	  of	  how	  the	  unique	  metabolism	  of	  tumor	  cells	  has	  been	  successfully	  exploited	  for	  therapy.	  	  Like	  anti-­‐folates,	  the	  potential	  utility	  of	  L-­‐asparaginase	  to	  treat	  cancer	  was	  discovered	  by	  accident	  and	  represents	  another	  example	  of	  rational	  drug	  design	  that	  was	  later	  revealed	  to	  exploit	  a	  metabolic	  difference	  between	  cancer	  and	  normal	  cells	  (Box	  2).	  	  It	  was	  found	  that	  ALL	  cells	  are	  functional	  asparagine	  (and	  glutamine)	  auxotrophs57.	  	  L-­‐asparaginase	  deaminates	  asparagine	  to	  aspartic	  acid,	  thereby	  limiting	  asparagine	  availability	  for	  cancer	  cells	  (Figure	  3).	  	  The	  bacterial	  L-­‐asparaginase	  used	  in	  the	  clinic	  has	  preferential	  selectivity	  for	  asparagine	  over	  the	  structurally	  related	  amino	  acid	  glutamine58;	  however,	  the	  enzyme	  retains	  some	  ability	  to	  degrade	  glutamine,	  and	  this	  activity	  may	  play	  a	  role	  in	  the	  dose	  limiting	  coagulopathy	  caused	  by	  imbalanced	  synthesis	  of	  pro-­‐	  and	  anti-­‐coagulant	  proteins58,	  59.	  	  	  However,	  glutamine	  is	  a	  crucial	  nutrient	  for	  many	  cancer	  cells	  and	  glutamine	  depletion	  may	  contribute	  to	  the	  effectiveness	  of	  the	  drug	  in	  ALL3,	  60.	  	  L-­‐aspariginase	  has	  little	  utility	  in	  the	  clinic	  outside	  of	  ALL,	  but	  other	  uses	  have	  not	  been	  explored	  since	  the	  early	  days	  of	  chemotherapy.	  	  Glutamine	  is	  the	  most	  abundant	  amino	  acid	  in	  serum	  and	  a	  key	  component	  of	  mammalian	  tissue	  culture	  media60,	  and	  several	  studies	  have	  identified	  a	  dependence	  of	  some	  cancer	  cells	  on	  the	  nutrient48-­‐50.	  	  	  Thus,	  use	  of	  L-­‐asparaginase,	  or	  analogous	  agents	  designed	  specifically	  to	  lower	  glutamine	  levels,	  may	  be	  effective	  to	  treat	  cancers	  other	  than	  ALL.	  	  A	  rational	  approach	  to	  identify	  other	  auxotrophies	  of	  cancer	  cells	  could	  lead	  to	  similar	  treatment	  strategies.	  	  Indeed,	  several	  types	  of	  cancer	  have	  low	  levels	  of	  arginosuccinate	  synthetase	  required	  for	  endogenous	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arginine	  synthesis3,	  and	  early	  experiments	  have	  suggested	  that	  tumors	  may	  be	  sensitive	  to	  arginase61.	  	  PEGylated	  arginine	  deiminase	  is	  an	  agent	  that	  lowers	  extracellular	  arginine	  levels	  and	  is	  currently	  in	  clinical	  trials	  for	  various	  solid	  tumors	  62.	  Early	  phase	  trials	  have	  shown	  this	  drug	  can	  be	  given	  safely,	  and	  some	  responses	  have	  been	  observed	  in	  both	  hepatocellular	  carcinoma	  and	  melanoma62,	  63.	  	  
Key	  issues	  in	  targeting	  cancer	  cell	  metabolism	  
Challenges	  in	  targeting	  metabolic	  pathways	  directly	  	   Because	  all	  cells	  rely	  on	  the	  same	  metabolic	  pathways	  to	  generate	  ATP,	  it	  is	  often	  assumed	  that	  drugs	  targeting	  metabolism	  would	  have	  detrimental	  effects	  on	  normal	  tissues.	  	  While	  this	  will	  be	  the	  case	  for	  some	  metabolic	  targets,	  the	  success	  of	  cytotoxic	  agents	  targeting	  folate	  metabolism	  and	  DNA	  synthesis	  illustrate	  that	  a	  therapeutic	  window	  can	  exist	  for	  drugs	  targeting	  metabolic	  pathways.	  	  These	  chemotherapies	  have	  side	  effects	  related	  to	  on-­‐target	  inhibition	  of	  the	  same	  enzymes	  in	  rapidly	  proliferating	  normal	  tissues	  such	  as	  the	  gut	  epithelium	  and	  bone	  marrow64.	  	  The	  common	  assumption	  that	  the	  therapeutic	  window	  obtained	  by	  these	  agents	  is	  due	  to	  the	  more	  rapid	  proliferation	  of	  cancer	  cells	  is	  not	  necessarily	  true.	  	  Proliferating	  cells	  in	  the	  gut	  have	  a	  cell	  cycle	  time	  estimated	  at	  30-­‐40	  hours	  and	  may	  proliferate	  as	  frequently	  as	  every	  10	  hours65,	  66.	  	  Hematopoiesis	  is	  also	  very	  fast	  as	  humans	  generate	  2	  million	  red	  cell	  precursors	  per	  second67.	  	  Cancer	  cells	  can	  proliferate	  at	  similar	  rates	  under	  optimal	  tissue	  culture	  conditions,	  but	  most	  cancer	  cells	  proliferate	  more	  slowly	  in	  vivo	  66,	  68.	  	  Despite	  this	  difference,	  sensitive	  cancers	  can	  be	  cured	  using	  these	  therapies.	  	  Tumor	  sensitivity	  to	  these	  agents	  can	  be	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accounted	  for	  in	  part	  by	  the	  loss	  of	  cell	  cycle	  checkpoints	  that	  accompany	  transformation	  (see	  69	  for	  review	  of	  chemotherapy	  killing	  mechanisms).	  	  However,	  the	  fact	  that	  folinic	  acid	  can	  rescue	  dihydrofolate	  reductase	  inhibition	  selectively	  in	  normal	  proliferating	  tissues	  (Figure	  2),	  and	  enhance	  the	  efficacy	  of	  5-­‐fluorouracil	  in	  colon	  cancer	  therapy70,	  argues	  that	  additional	  metabolic	  differences	  exist	  in	  cancer	  cells	  that	  also	  contribute	  to	  the	  therapeutic	  window.	  	  A	  better	  understanding	  of	  the	  molecular	  mechanisms	  underlying	  why	  some	  cancer	  cells	  are	  more	  dependent	  on	  specific	  metabolic	  pathways	  could	  result	  in	  more	  effective	  metabolic	  targeting	  with	  fewer	  effects	  on	  normal	  proliferating	  cells.	  	   Unwanted	  toxicity	  caused	  by	  effects	  on	  proliferating	  normal	  cells	  is	  likely	  to	  be	  a	  major	  challenge	  in	  developing	  drugs	  that	  target	  proliferative	  cell	  metabolism.	  	  Often	  more	  than	  one	  pathway	  exists	  to	  generate	  the	  same	  metabolic	  end	  product,	  and	  redundant	  pathways	  present	  in	  normal	  cells	  that	  are	  lost	  in	  cancer	  cells	  may	  allow	  for	  a	  therapeutic	  window.	  	  However,	  this	  same	  redundancy	  may	  also	  impair	  efficacy	  of	  drugs	  in	  tumors	  that	  can	  use	  more	  than	  one	  pathway.	  	  For	  instance,	  the	  success	  of	  targeting	  ATP	  citrate	  lyase	  as	  a	  means	  to	  block	  cytoplasmic	  acetyl-­‐coA	  levels	  is	  limited	  in	  part	  by	  the	  generation	  of	  acetyl-­‐coA	  via	  another	  route71.	  	  Nevertheless,	  there	  is	  mounting	  evidence	  that	  genetic	  changes	  associated	  with	  cancer	  create	  addictions	  to	  specific	  metabolic	  pathways4,	  5,	  and	  cancer	  cells	  often	  have	  chromosomal	  deletions	  that	  could	  eliminate	  enzymes	  necessary	  for	  the	  use	  of	  redundant	  pathways.	  	  Combining	  agents	  to	  target	  complementary	  metabolic	  pathways	  might	  be	  another	  strategy	  to	  reduce	  the	  dose	  of	  individual	  drugs	  and	  limit	  unwanted	  effects	  on	  normal	  cells.	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   A	  therapeutic	  window	  does	  not	  exist	  for	  some	  targets	  in	  metabolism,	  but	  drugging	  alternative	  targets	  in	  the	  same	  pathway	  may	  be	  feasible.	  	  While	  it	  has	  never	  been	  used	  to	  treat	  cancer,	  the	  mitochondrial	  uncoupling	  agent	  2,4-­‐dinitrophenol	  (DNP)	  was	  used	  as	  a	  weight	  loss	  agent	  in	  the	  1930s72.	  	  	  By	  uncoupling	  mitochondrial	  electron	  transport	  from	  ATP	  synthesis	  (Figure	  3),	  agents	  like	  DNP	  cause	  energy	  released	  from	  nutrient	  oxidation	  to	  be	  lost	  as	  heat	  and	  induce	  energy	  stress	  in	  cells.	  	  Unfortunately,	  only	  slight	  overdoses	  of	  DNP	  result	  in	  lethal	  hyperthermia.	  	  However,	  metformin	  also	  targets	  oxidative	  phosphorylation	  in	  a	  different	  way	  (Figure	  3),	  is	  well	  tolerated,	  and	  is	  one	  of	  the	  most	  commonly	  prescribed	  drugs	  in	  the	  world.	  	  By	  slowing	  mitochondrial	  ATP	  generation,	  metformin	  causes	  mild	  cellular	  energy	  stress27.	  	  Metformin	  has	  an	  on-­‐target,	  dose-­‐dependent	  side	  effect	  of	  inducing	  lactic	  acidosis.	  	  Complex	  I	  inhibition	  by	  metformin	  decreases	  mitochondrial	  oxidation	  of	  NADH	  to	  NAD+.	  	  Regenerating	  NAD+	  is	  necessary	  to	  allow	  continued	  glycolytic	  flux,	  and	  lactate	  synthesis	  allows	  regeneration	  of	  NAD+	  from	  NADH	  in	  the	  absence	  of	  mitochondrial	  electron	  transport.	  	  Thus,	  increased	  lactate	  production	  is	  an	  inevitable	  consequence	  of	  increased	  complex	  I	  inhibition	  and	  defines	  the	  therapeutic	  window	  for	  this	  class	  of	  drugs.	  	  Whether	  this	  window	  is	  large	  enough	  to	  achieve	  doses	  in	  vivo	  that	  have	  direct	  growth	  inhibitory	  effects	  on	  tumors	  remains	  to	  be	  determined.	  	   Metabolism	  is	  often	  viewed	  as	  a	  housekeeping	  function	  for	  cells,	  while	  signaling	  pathways	  are	  viewed	  as	  unique	  pathways	  acting	  only	  in	  specific	  cell	  types	  and	  physiological	  situations.	  	  However,	  with	  the	  exception	  of	  gain-­‐of-­‐function	  gene	  mutations,	  there	  is	  no	  target	  unique	  to	  cancer	  cells.	  	  Successful	  targeted	  therapies	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take	  advantage	  of	  a	  relative	  dependence	  of	  cancer	  cells	  on	  specific	  pathways.	  	  Similarly,	  cancer	  cells	  depend	  on	  specific	  metabolic	  pathways,	  and	  identifying	  these	  dependencies	  is	  the	  key	  to	  generating	  drugs	  against	  metabolic	  enzymes	  that	  have	  minimal	  effects	  on	  normal	  tissues.	  	  
Metabolic	  flux	  in	  cancer	  cells	  is	  not	  well	  understood	  Resistance	  to	  therapy	  is	  an	  issue	  with	  all	  cancer	  treatments	  and	  metabolism	  is	  a	  complex	  network	  with	  built	  in	  plasticity	  that	  may	  allow	  the	  cell	  to	  overcome	  inhibition	  at	  a	  single	  enzymatic	  step.	  	  This	  further	  highlights	  the	  importance	  of	  understanding	  precisely	  how	  metabolic	  pathways	  are	  regulated	  in	  cancer	  cells	  in	  
vivo.	  	  Flux	  through	  pathways,	  rather	  than	  levels	  of	  individual	  metabolites,	  provide	  the	  cell	  with	  the	  ability	  to	  continually	  generate	  ATP	  to	  support	  cell	  survival,	  or	  to	  provide	  critical	  biosynthetic	  precursors	  for	  cell	  growth.	  	  Thus,	  understanding	  flux	  through	  the	  cancer	  cell	  metabolic	  network	  is	  likely	  to	  provide	  more	  insight	  into	  successful	  enzyme	  targets	  than	  ascertainment	  of	  individual	  metabolite	  levels	  alone.	  Recent	  advances	  in	  metabolite	  profiling	  methodologies	  provide	  new	  tools	  to	  understand	  flux	  through	  pathways,	  and	  will	  enhance	  our	  understanding	  of	  cancer	  metabolism.	  	  Furthermore,	  increased	  application	  of	  techniques	  such	  as	  MR	  spectroscopy,	  including	  dynamic	  nuclear	  polarization	  to	  generate	  hyperpolarized	  
13C-­‐labeled	  metabolites	  whose	  metabolism	  can	  be	  tracked	  in	  tumors,	  can	  allow	  direct	  visualization	  of	  how	  metabolism	  is	  altered	  as	  a	  result	  of	  new	  therapies	  in	  patients73,	  74.	  	  These	  approaches	  to	  track	  metabolism	  in	  vivo	  will	  be	  especially	  critical	  to	  understand	  how	  cell	  metabolism	  is	  influenced	  by	  the	  tumor	  microenvironment5,	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and	  will	  help	  select	  the	  right	  patients	  for	  specific	  drugs	  targeting	  metabolism.	  	  
Potential	  of	  Metabolic	  Enzymes	  as	  Drug	  Targets	  Mutations	  in	  oncogenes	  or	  tumor	  suppressor	  genes	  result	  in	  addiction	  of	  cancer	  cells	  to	  downstream	  signaling	  events2,	  75.	  	  	  These	  genetic	  events	  define	  an	  ideal	  set	  of	  possible	  targets	  for	  cancer	  therapy,	  but	  unfortunately	  many	  of	  the	  gene	  products	  are	  transcription	  factors	  or	  signaling	  molecules	  that	  rely	  on	  protein-­‐protein	  interactions	  and	  present	  challenges	  to	  drug	  development.	  	  As	  a	  result,	  efforts	  have	  focused	  on	  targeting	  other	  tractable	  signaling	  molecules	  in	  a	  key	  pathway	  associated	  with	  the	  genetic	  event.	  	  These	  strategies	  have	  had	  limited	  success	  in	  the	  clinic,	  arguing	  that	  blocking	  single	  downstream	  signaling	  targets	  is	  insufficient	  to	  block	  the	  transforming	  effects	  of	  some	  driver	  mutations.	  	  Altered	  expression	  of	  metabolic	  enzymes	  or	  changes	  in	  metabolic	  pathway	  regulation	  are	  also	  downstream	  of	  many	  oncogenes	  and	  tumor	  suppressor	  genes,	  and	  cancers	  with	  specific	  genetic	  lesions	  are	  addicted	  to	  at	  least	  some	  of	  these	  metabolic	  changes1,	  4,	  
76.	  	  In	  addition,	  ATP	  is	  necessary	  for	  survival	  of	  all	  cells,	  and	  the	  ability	  to	  convert	  nutrients	  into	  biomass	  is	  critical	  for	  all	  cancer	  cells.	  	  Thus,	  attacking	  metabolism	  as	  a	  downstream	  consequence	  of	  driver	  mutations	  is	  an	  attractive	  strategy	  because	  it	  is	  central	  to	  the	  growth	  and	  survival	  of	  cancer	  cells.	  	  Furthermore,	  many	  metabolic	  enzymes	  are	  amenable	  to	  targeting	  with	  small	  molecules.	  	  
Tumor	  metabolism	  can	  be	  safely	  targeted	  	  It	  is	  possible	  to	  safely	  target	  central	  metabolic	  pathways	  in	  patients.	  	  The	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small	  molecule	  dichloroacetate	  (DCA)	  is	  used	  to	  treat	  patients	  with	  lactic	  acidosis	  resulting	  from	  rare	  inborn	  errors	  of	  mitochondrial	  metabolism.	  	  At	  least	  one	  target	  of	  DCA	  is	  pyruvate	  dehydrogenase	  kinase	  (PDK)	  (Figure	  3).	  	  PDK	  expression	  is	  increased	  in	  many	  cancers	  as	  a	  result	  of	  increased	  activation	  of	  the	  HIF	  transcription	  factor77,	  78.	  	  PDK	  is	  a	  negative	  regulator	  of	  the	  pyruvate	  dehydrogenase	  complex	  (PDH)79.	  	  PDH	  catalyzes	  the	  oxidative	  decarboxylation	  of	  pyruvate	  to	  acetyl-­‐CoA,	  allowing	  pyruvate	  entry	  into	  the	  tricarboxylic	  acid	  cycle	  and	  away	  from	  lactate	  production.	  	  Thus,	  DCA-­‐mediated	  inhibition	  of	  PDK	  leads	  to	  activation	  of	  PDH,	  increased	  metabolism	  of	  pyruvate	  to	  acetyl-­‐CoA,	  and	  decreased	  lactate	  production.	  	  DCA	  can	  alter	  mitochondrial	  membrane	  potential	  and	  inhibit	  lactate	  production	  in	  cancer	  model	  systems80,	  and	  has	  been	  shown	  to	  alter	  mitochondria	  in	  human	  glioblastoma81.	  	  Importantly,	  even	  at	  doses	  that	  influence	  mitochondrial	  membrane	  potential,	  DCA	  is	  well	  tolerated	  by	  patients81.	  	  While	  there	  is	  insufficient	  data	  to	  know	  whether	  DCA	  will	  provide	  clinical	  benefit,	  these	  studies	  demonstrate	  that	  a	  sufficient	  therapeutic	  window	  can	  exist	  to	  target	  cell	  metabolism	  in	  patients.	  
	  
Approaches	  to	  target	  cancer	  metabolism	  Despite	  a	  renewed	  interest	  in	  exploring	  metabolic	  enzymes	  as	  targets	  for	  cancer	  therapy,	  very	  few	  molecules	  that	  target	  central	  carbon	  metabolism	  are	  currently	  in	  clinical	  trials	  (Table	  1).	  	  However,	  mounting	  evidence	  supports	  several	  metabolic	  enzymes	  as	  candidate	  targets	  and	  studies	  using	  tool	  compounds	  have	  yielded	  encouraging	  results	  in	  preclinical	  cancer	  models.	  	  New	  molecules	  directed	  against	  metabolic	  enzymes	  will	  likely	  enter	  clinical	  studies	  in	  the	  next	  several	  years.	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Such	  compounds	  have	  the	  potential	  to	  limit	  macromolecular	  synthesis	  needed	  for	  cell	  growth,	  a	  strategy	  employed	  by	  existing	  drugs	  targeting	  nucleic	  acid	  synthesis.	  	  Alternatively,	  targeting	  metabolism	  can	  limit	  pathways	  important	  to	  supply	  nutrients	  to	  the	  cell	  and	  impair	  bioenergetics	  to	  prevent	  an	  adaptive	  response	  to	  cell	  stress.	  	  This	  latter	  approach	  is	  more	  likely	  to	  be	  synergistic	  with	  non-­‐metabolic	  therapies	  that	  also	  impair	  nutrient	  uptake54.	  	  Enzyme	  targets	  that	  fall	  into	  both	  classes	  are	  summarized	  in	  Table	  1.	  	  These	  approaches	  could	  have	  seemingly	  opposite	  effects	  on	  some	  metabolic	  phenotypes.	  	  For	  instance,	  both	  DCA	  and	  metformin	  target	  mitochondrial	  physiology,	  yet	  DCA	  decreases	  lactate	  production	  and	  is	  used	  to	  treat	  lactic	  acidosis	  while	  metformin	  increases	  lactate	  production	  and	  has	  lactic	  acidosis	  as	  an	  important	  side	  effect.	  	  While	  paradoxical,	  there	  is	  evidence	  to	  support	  both	  as	  potentially	  beneficial	  in	  cancer	  treatment.	  	  By	  increasing	  glucose	  entry	  into	  the	  TCA	  cycle,	  DCA	  directs	  carbon	  away	  from	  lactate	  production80	  (Figure	  3),	  and	  as	  a	  consequence	  may	  direct	  metabolism	  away	  from	  efficient	  biosynthetic	  reactions1.	  	  Metformin	  on	  the	  other	  hand,	  inhibits	  the	  transfer	  of	  electrons	  from	  NADH	  in	  the	  mitochondria	  to	  the	  electron	  transport	  chain	  (Figure	  3).	  	  This	  increases	  reliance	  on	  lactate	  production	  as	  a	  means	  to	  cycle	  NADH	  back	  to	  NAD+,	  impairs	  mitochondrial	  production	  of	  ATP,	  and	  causes	  cellular	  energy	  stress26,	  31.	  	  Both	  approaches	  to	  impair	  metabolism	  could	  have	  therapeutic	  benefit	  in	  the	  right	  context.	  	  The	  former	  strategy	  is	  likely	  to	  be	  more	  effective	  in	  tumors	  with	  increased	  reliance	  on	  high	  glucose	  uptake	  with	  lactate	  production,	  while	  the	  latter	  might	  synergize	  with	  other	  therapies	  that	  induce	  energy	  stress.	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Directly	  targeting	  glucose	  metabolism	  	  Various	  agents	  have	  been	  shown	  to	  block	  glucose	  use	  by	  cancer	  cells,	  but	  to	  date	  no	  specific	  glucose	  transport	  inhibitors	  have	  been	  reported.	  	  GLUT1	  is	  the	  glucose	  transporter	  with	  the	  largest	  tissue	  distribution	  and	  is	  thought	  to	  be	  the	  transporter	  responsible	  for	  basal	  glucose	  uptake	  in	  most	  cancer	  and	  normal	  cells82,	  
83	  (Figure	  3).	  	  Although	  GLUT1	  is	  expressed	  at	  much	  higher	  levels	  in	  cancer	  cells	  than	  in	  normal	  cells	  it	  may	  be	  difficult	  to	  inhibit	  glucose	  uptake	  directly	  in	  tumors	  without	  an	  effect	  on	  normal	  tissues.	  	  Nevertheless,	  partial	  inhibition	  of	  glucose	  uptake	  may	  still	  sensitize	  cancer	  cells	  to	  other	  drugs	  (see	  84	  for	  review	  of	  various	  studies).	  	  Many	  of	  these	  studies	  rely	  on	  the	  withdrawal	  of	  glucose	  from	  cells	  in	  culture,	  illustrating	  the	  need	  for	  pharmacological	  agents	  that	  inhibit	  glucose	  uptake.	  	  There	  are	  at	  least	  thirteen	  passive	  glucose	  transporters,	  most	  of	  which	  have	  poorly	  understood	  functions.	  	  Interestingly,	  some	  of	  these,	  such	  as	  GLUT3,	  are	  not	  expressed	  in	  most	  normal	  tissues	  but	  can	  be	  expressed	  at	  high	  levels	  in	  cancer	  suggesting	  these	  transporters	  as	  possible	  targets82.	  	  Antibodies	  that	  selectively	  target	  GLUT3	  or	  other	  nutrient	  transporters	  with	  restricted	  expression	  may	  represent	  another	  way	  to	  block	  nutrient	  uptake	  and	  starve	  cancer	  cells.	  2-­‐deoxyglucose	  (2DG)	  is	  an	  inhibitor	  of	  glucose	  metabolism	  because	  it	  is	  phosphorylated	  in	  cells	  by	  hexokinase	  (HK)	  to	  make	  2DG-­‐6-­‐phosphate,	  a	  competitive	  inhibitor	  of	  enzymes	  that	  metabolize	  glucose-­‐6-­‐phosphate.	  	  Cells	  exposed	  to	  sufficient	  amounts	  of	  2DG	  undergo	  growth	  arrest	  and/or	  apoptosis85,	  and	  2DG	  may	  potentiate	  standard	  cytotoxic	  chemotherapy84,	  86.	  	  2DG	  has	  been	  tested	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as	  an	  anti-­‐cancer	  agent	  in	  patients87,	  but	  when	  given	  to	  glioblastoma	  patients	  at	  doses	  sufficient	  to	  limit	  glucose	  metabolism	  in	  cancer	  cells,	  significant	  toxicity	  was	  observed88,	  89.	  	  Lower	  dose	  2DG	  is	  better	  tolerated	  by	  patients,	  but	  limited	  efficacy	  has	  been	  observed	  at	  these	  doses90.	  	  However,	  because	  2DG	  is	  a	  competitive	  inhibitor	  of	  glucose,	  and	  glucose	  is	  present	  at	  millimolar	  concentrations	  in	  the	  blood,	  it	  remains	  to	  be	  determined	  whether	  a	  sufficient	  therapeutic	  window	  exists	  to	  competitively	  inhibit	  glucose	  uptake	  or	  the	  proximal	  enzymes	  in	  glycolysis.	  It	  appears	  that	  cancer	  cells	  preferentially	  rely	  on	  specific	  isoforms	  of	  glycolytic	  enzymes.	  Therefore,	  isoform	  selective	  targeting	  may	  provide	  an	  alternative	  approach	  to	  modulate	  glucose	  metabolism	  in	  cancer	  cells.	  	  HK	  is	  responsible	  for	  trapping	  glucose	  in	  cells	  (Figure	  3)	  and	  at	  least	  some	  cancers	  are	  specifically	  dependent	  on	  the	  HK2	  isoform	  of	  this	  enzyme	  91,	  92.	  	  HK2	  is	  normally	  expressed	  in	  skeletal	  muscle	  and	  adipose	  tissue,	  suggesting	  a	  window	  to	  target	  HK2	  without	  risking	  on-­‐target	  side	  effects	  in	  other	  normal	  tissues	  that	  express	  another	  isoform.	  	  The	  properties	  of	  HK2	  that	  select	  for	  its	  expression	  in	  cancers	  are	  not	  clear.	  	  Nevertheless,	  the	  fact	  that	  HK2	  is	  specifically	  required	  by	  some	  cancers	  suggests	  that	  re-­‐expression	  of	  another	  hexokinase	  isoform	  is	  unlikely	  to	  provide	  an	  escape	  mechanism	  for	  tumors	  treated	  with	  an	  HK2-­‐selective	  inhibitor.	  	  An	  association	  between	  hexokinase	  and	  mitochondria	  influences	  apoptosis	  regulation93,	  and	  compounds	  isolated	  from	  plants	  that	  disrupt	  this	  association	  are	  toxic	  to	  cancer	  cells	  in	  culture94.	  	  HK	  is	  also	  a	  target	  of	  3-­‐bromopyruvate,	  a	  compound	  shown	  to	  be	  toxic	  to	  cancer	  cells	  91,	  95.	  	  However,	  3-­‐bromopyruvate	  is	  also	  toxic	  to	  some	  cancer	  cells	  at	  concentrations	  that	  are	  too	  low	  to	  inhibit	  HK	  and	  it	  has	  been	  argued	  that	  the	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combined	  inhibition	  of	  multiple	  metabolic	  enzymes	  accounts	  for	  the	  toxic	  effects	  of	  this	  compound	  on	  cancer	  cells96.	  	  Pyruvate	  kinase	  is	  another	  glycolytic	  enzyme	  for	  which	  isoform	  selective	  targeting	  may	  be	  therapeutically	  beneficial	  (Figure	  3).	  	  There	  are	  two	  pyruvate	  kinase	  genes	  in	  mammals,	  each	  producing	  two	  distinct	  gene	  products	  by	  alternative	  splicing97,	  98.	  	  Most	  tissues	  express	  a	  product	  of	  the	  PK-­‐M	  gene	  that	  is	  alternatively	  spliced	  to	  produce	  either	  the	  PKM1	  or	  PKM2	  isoform.	  	  All	  cancer	  cells	  express	  PKM2,	  while	  many	  differentiated	  tissues	  express	  PKM197.	  	  PKM2	  expression	  promotes	  aerobic	  glycolysis	  and	  is	  selected	  for	  during	  growth	  of	  xenograft	  tumors	  in	  mice99.	  	  PKM1	  is	  a	  constitutively	  active	  enzyme,	  while	  PKM2	  is	  unique	  among	  pyruvate	  kinase	  isoforms	  in	  that	  its	  enzyme	  activity	  is	  inhibited	  by	  binding	  to	  tyrosine-­‐phosphorylated	  proteins	  downstream	  of	  cell	  growth	  signals100.	  	  Surprisingly,	  it	  is	  this	  ability	  to	  inhibit	  the	  enzyme	  that	  appears	  important	  for	  promotion	  of	  aerobic	  glycolysis	  and	  cell	  proliferation.	  	  Selection	  for	  a	  less	  active	  form	  of	  pyruvate	  kinase	  may	  help	  divert	  glucose	  metabolites	  upstream	  of	  pyruvate	  kinase	  into	  biosynthetic	  pathways5,	  97,	  100.	  	  Efforts	  have	  been	  made	  to	  selectively	  inhibit	  PKM2101,	  102.	  	  Peptide	  aptamers	  that	  promote	  the	  less	  active	  form	  of	  pyruvate	  kinase	  have	  been	  shown	  cause	  energy	  stress	  and	  cell	  death	  in	  cultured	  cancer	  cells101,	  and	  more	  modest	  effects	  were	  observed	  using	  small	  molecule	  inhibitors	  of	  PKM2102.	  	  Targeting	  PKM2	  with	  shRNA	  can	  slow	  cell	  proliferation	  in	  cell	  culture99,	  however	  these	  cells	  retain	  the	  ability	  to	  proliferate	  even	  with	  the	  near	  complete	  absence	  of	  pyruvate	  kinase	  activity.	  	  These	  findings	  suggest	  that	  activation	  of	  PKM2	  to	  restore	  the	  high	  pyruvate	  kinase	  activity	  state	  found	  in	  normal	  tissues	  may	  be	  an	  alternative	  strategy	  to	  target	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the	  pyruvate	  kinase	  step	  in	  cancer.	  	  Isoform-­‐specific	  small	  molecule	  activators	  of	  PKM2	  have	  been	  reported103,	  104.	  	  Whether	  these	  compounds	  can	  induce	  the	  same	  growth	  disadvantage	  in	  vivo	  that	  is	  observed	  in	  PKM1-­‐expressing	  cells	  remains	  to	  be	  determined.	  	  Because	  PKM2	  is	  unique	  among	  pyruvate	  kinase	  isoforms	  in	  having	  the	  ability	  to	  switch	  between	  a	  low	  and	  high	  activity	  state,	  it	  is	  possible	  that	  disrupting	  this	  dynamic	  capability	  with	  either	  enzyme	  inhibitors	  or	  activators	  could	  be	  therapeutically	  beneficial.	  	  However,	  PKM2	  is	  also	  expressed	  in	  many	  normal	  tissues97,	  and	  it	  remains	  to	  be	  determined	  whether	  activation	  or	  inhibition	  of	  the	  enzyme	  in	  these	  tissues	  will	  result	  in	  unacceptable	  toxicity.	  Another	  example	  of	  a	  regulatory	  enzyme	  in	  glycolysis	  with	  isoform	  selectivity	  in	  some	  cancers	  is	  fructose-­‐6-­‐phosphate-­‐2-­‐kinase	  (PFK2)	  (Figure	  3).	  	  By	  generating	  fructose-­‐2,6-­‐bisphosphate	  (F-­‐2,6-­‐BP),	  PFK2	  activates	  phosphofructokinase	  (PFK1)	  to	  increase	  flux	  through	  this	  step	  of	  glycolysis.	  	  Most	  PFK2	  isoforms	  are	  bifunctional	  enzymes	  with	  both	  kinase	  and	  phosphatase	  activity,	  and	  thus	  can	  also	  catalyze	  the	  destruction	  of	  F-­‐2,6-­‐BP	  and	  decrease	  PFK1	  activity105.	  	  PFK2FB3	  is	  the	  isoform	  expressed	  in	  many	  cancers	  and	  is	  required	  for	  anchorage	  independent	  growth	  of	  RAS-­‐driven	  tumors106,	  107.	  	  PFK2FB3	  has	  almost	  no	  phosphatase	  activity,	  and	  kinase	  activity	  is	  influenced	  by	  several	  factors	  implicated	  in	  controlling	  cancer	  metabolism	  including	  metabolite	  levels	  as	  well	  as	  RAS,	  MYC,	  and	  AMPK	  signaling105,	  108,	  109.	  	  Small	  molecule	  inhibitors	  of	  PFK2FB3	  have	  been	  reported	  to	  have	  a	  cytostatic	  effect	  on	  Ras-­‐transformed	  cancer	  cells51.	  	  The	  compound	  decreases	  F-­‐2,6-­‐BP	  levels	  and	  impairs	  growth	  of	  xenograft	  tumors51,	  raising	  interest	  in	  this	  enzyme	  as	  a	  target	  for	  cancer	  therapy.	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Inhibiting	  lactate	  production	  or	  transport	  Because	  lactate	  is	  excreted	  from	  the	  cell,	  inhibiting	  lactate	  production	  or	  lactate	  transport	  out	  of	  the	  cell	  are	  two	  strategies	  to	  directly	  target	  the	  Warburg	  effect	  in	  cancer.	  	  The	  family	  of	  monocarboxylate	  transporters	  (MCT)	  are	  the	  major	  proteins	  responsible	  for	  lactate	  export	  in	  glycolytic	  cells	  including	  cancer	  cells	  (Figure	  3)110-­‐112.	  	  There	  is	  evidence	  that	  a	  symbiotic	  relationship	  exists	  among	  different	  cells	  within	  a	  tumor	  whereby	  some	  cells	  rely	  on	  lactate	  produced	  by	  other	  cells	  as	  a	  fuel	  source,	  and	  disrupting	  lactate	  transport	  can	  starve	  cells	  dependent	  on	  lactate	  for	  survival113.	  	  Targeting	  MCTs	  using	  small	  molecules	  also	  inhibits	  proliferation	  of	  lymphocytes	  that	  rely	  on	  aerobic	  glycolysis114,	  115.	  	  This	  suggests	  impaired	  immune	  function	  could	  be	  a	  side	  effect	  of	  targeting	  lactate	  export	  in	  cancer.	  	  It	  also	  suggests	  drugs	  targeting	  cancer	  metabolism	  may	  have	  a	  role	  as	  immunosuppressive	  therapies.	  	  Additional	  potential	  side	  effects	  from	  inhibiting	  lactate	  transport	  include	  negatively	  impacting	  other	  normal	  tissues	  such	  as	  the	  liver,	  muscles	  and	  brain	  that	  rely	  on	  lactate	  as	  a	  fuel	  in	  certain	  physiological	  situations116.	  	  Lactate	  dehydrogenase	  (LDH)	  is	  the	  enzyme	  that	  interconverts	  pyruvate	  and	  NADH	  with	  lactate	  and	  NAD+	  (Figure	  3).	  	  When	  LDHA	  is	  knocked	  down	  using	  RNA	  interference,	  cancer	  cell	  proliferation	  is	  severely	  impaired	  both	  in	  vitro	  and	  in	  vivo	  52,	  
117.	  	  LDHA	  is	  the	  form	  of	  LDH	  expressed	  in	  many	  cancer	  cells,	  and	  inhibitors	  of	  this	  enzyme	  are	  being	  developed.	  	  Most	  non-­‐cancerous	  tissues	  are	  not	  dependent	  on	  LDHA,	  and	  LDHA	  can	  be	  selectively	  inhibited	  over	  other	  forms	  of	  LDH118.	  	  Furthermore,	  LDHA	  inhibitors	  slow	  the	  growth	  of	  xenograft	  tumors	  in	  mice	  and	  can	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induce	  tumor	  regression	  when	  combined	  with	  nicotinamide	  phosphoribosyltransferase	  inhibitors	  (NAMPT)53,	  supporting	  LDHA	  as	  a	  promising	  therapeutic	  target.	  	  
Targeting	  NAD+	  metabolism	  	   Cells	  possess	  a	  limited	  pool	  of	  NAD+/NADH,	  yet	  these	  molecules	  exist	  as	  important	  cofactors	  in	  metabolic	  reactions	  involving	  oxidation/reduction.	  	  They	  are	  also	  substrates	  for	  enzymes	  such	  as	  sirtuins	  and	  poly-­‐ADP-­‐ribose	  polymerases	  involved	  in	  the	  regulation	  of	  numerous	  processes	  related	  to	  cancer	  including	  DNA	  repair,	  inflammation	  and	  protein	  acetylation	  119.	  	  Unlike	  oxidation/reduction	  reactions,	  these	  latter	  reactions	  consume	  NAD+	  and	  deplete	  the	  cellular	  pool	  of	  this	  important	  cofactor.	  	  Interestingly,	  NAMPT,	  the	  enzyme	  involved	  in	  regenerating	  NAD+	  via	  a	  salvage	  pathway	  from	  nicotinamide	  and	  phosphoribosyl-­‐pyrophosphate,	  was	  identified	  as	  the	  target	  of	  a	  molecule	  identified	  in	  a	  screen	  to	  find	  novel	  cytotoxic	  compounds120.	  	  Cells	  treated	  with	  NAMPT	  inhibitors	  die	  as	  a	  result	  of	  NAD+	  depletion,	  and	  NAMPT	  inhibition	  has	  shown	  activity	  as	  an	  anti-­‐cancer	  agent	  in	  pre-­‐clinical	  cancer	  models119.	  	  	  Because	  NAD+	  is	  a	  required	  cofactor	  for	  the	  GAPDH	  step	  of	  glycolysis,	  cells	  must	  regenerate	  NAD+	  from	  NADH	  to	  allow	  continued	  flow	  of	  glucose	  carbon	  through	  glycolysis	  (Figure	  3).	  	  Consistent	  with	  NAMPT	  inhibitors	  limiting	  glucose	  metabolism	  in	  cells	  with	  high	  activity	  of	  NAD+	  consuming	  enzymes,	  NAMPT	  inhibition	  in	  cells	  has	  an	  effect	  primarily	  on	  the	  cytosolic	  (rather	  than	  the	  mitochondrial)	  NAD+	  pool121.	  	  NAMPT	  inhibition	  can	  also	  be	  toxic	  to	  lymphocytes122,	  suggesting	  that	  use	  of	  NAMPT	  inhibitors	  in	  patients	  might	  be	  limited	  by	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immunosuppression.	  	  Mild	  lymphopenia	  was	  observed	  in	  early	  trials	  of	  NAMPT	  inhibitors,	  but	  thrombocytopenia	  was	  the	  dose	  limiting	  toxicity123.	  	  Limited	  clinical	  efficacy	  has	  been	  observed	  thus	  far,	  although	  work	  is	  ongoing	  to	  develop	  more	  potent	  compounds	  and	  define	  those	  patients	  most	  likely	  to	  benefit	  from	  NAMPT	  inhibition124.	  	  
Targeting	  metabolic	  enzymes	  that	  are	  mutated	  in	  cancer	  The	  idea	  that	  metabolic	  alterations	  are	  not	  the	  same	  across	  all	  cancers	  is	  supported	  by	  the	  discovery	  of	  a	  novel	  metabolic	  flux	  dictated	  by	  isocitrate	  dehydrogenase	  (IDH)	  mutations.	  	  Point	  mutations	  in	  IDH1	  and	  IDH2	  found	  in	  cancer	  always	  involve	  a	  residue	  in	  the	  active	  site	  of	  only	  one	  allele125-­‐127,	  and	  lead	  to	  production	  of	  2-­‐hydroxyglutarate	  (2HG)	  -­‐	  a	  metabolite	  found	  only	  at	  very	  low	  levels	  in	  normal	  cells128-­‐130.	  	  IDH	  mutations	  define	  a	  clinically	  distinct	  subset	  of	  both	  glioma	  and	  leukemia	  suggesting	  that	  these	  mutations	  contribute	  to	  a	  unique	  biology	  within	  each	  tumor	  type125,	  127,	  131,	  132.	  	  It	  is	  not	  clear	  how	  IDH	  mutation	  and	  2HG	  production	  promote	  cancer,	  nor	  is	  it	  clear	  whether	  existing	  cancers	  remain	  dependent	  on	  the	  abnormal	  enzyme	  activity;	  however,	  2HG	  is	  an	  inhibitor	  of	  α-­‐ketoglutarate	  (αKG)-­‐dependent	  dioxygenases133-­‐135.	  	  αKG-­‐dependent	  dioxygenases	  are	  involved	  in	  an	  oxygen	  sensing	  pathway	  that	  leads	  to	  stabilization	  of	  the	  HIF	  transcription	  factor	  that	  controls	  expression	  of	  many	  genes	  important	  for	  cancer	  and	  metabolic	  regulation10,	  11.	  	  αKG-­‐dependent	  dioxygenases	  are	  also	  involved	  in	  demethylation	  reactions	  that	  affect	  chromatin	  structure	  having	  plieotropic	  effects	  on	  global	  transcription	  and	  cellular	  differentiation136,	  137,	  and	  this	  methylation	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pattern	  is	  altered	  in	  cells	  with	  IDH1	  mutations133,	  134.	  	  	  Thus,	  when	  developed,	  small	  molecules	  that	  inhibit	  2HG	  production	  by	  mutant	  IDH	  may	  restore	  normal	  αKG-­‐dependent	  dioxygenase	  function	  and	  normalize	  both	  HIF	  levels	  and	  chromatin	  structure.	  	  In	  addition,	  because	  these	  dioxygenases	  are	  influenced	  by	  the	  
αKG/succinate	  ratio,	  delivery	  of	  αKG-­‐analogs	  may	  be	  another	  way	  to	  restore	  normal	  dioxygenase	  activity.	  	  These	  cell	  permeable	  esters	  of	  αKG	  can	  both	  raise	  αKG	  levels	  and	  increase	  dioxygenase	  activity138.	  	  This	  latter	  strategy	  has	  seen	  some	  success	  in	  models	  of	  human	  cancer	  with	  abnormal	  αKG/succinate	  ratios	  caused	  by	  loss	  of	  function	  mutations	  in	  succinate	  dehydrogenase	  or	  fumarate	  hydratase138.	  	  
Additional	  strategies	  to	  target	  glutamine	  metabolism	  	   As	  discussed	  above,	  glutamine	  is	  an	  important	  nutrient	  for	  some	  cancer	  cells.	  Glutamine	  is	  the	  major	  source	  of	  nitrogen	  for	  nucleotide	  and	  amino	  acid	  synthesis,	  but	  many	  cells	  metabolize	  glutamine	  in	  excess	  of	  their	  nitrogen	  requirement.	  	  Glutamine	  also	  plays	  an	  important	  role	  in	  replenishing	  TCA	  cycle	  intermediates	  depleted	  by	  biosynthetic	  reactions	  (Figure	  3)139.	  	  	  The	  enzyme	  glutaminase	  catalyzes	  glutamine	  to	  glutamate	  conversion	  on	  the	  pathway	  to	  αKG	  production.	  	  Glutaminase	  has	  two	  major	  isoforms	  in	  mammals,	  GLS1	  and	  GLS2,	  and	  expression	  of	  these	  enzymes	  can	  have	  opposite	  effects	  on	  cell	  proliferation140.	  	  GLS1	  is	  an	  important	  downstream	  effector	  of	  MYC	  and	  promotes	  glutamine	  entry	  into	  the	  TCA	  cycle49,	  50,	  while	  GLS2	  is	  regulated	  by	  p53	  and	  influences	  the	  cellular	  redox	  state141.	  	  	  These	  different	  functions	  of	  GLS1	  and	  GLS2	  likely	  play	  key	  roles	  in	  cancer	  metabolism,	  and	  targeting	  glutaminase	  activity	  can	  selectively	  inhibit	  the	  growth	  of	  transformed	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cells142,	  143.	  	  Blocking	  GLS1	  activity	  can	  prevent	  glutamine	  entry	  into	  cells	  as	  a	  source	  of	  2HG	  production	  by	  mutant	  IDH1,	  and	  slow	  the	  growth	  of	  these	  cells143.	  	  GLS1	  was	  also	  identified	  as	  the	  target	  of	  a	  molecule	  that	  blocks	  cell	  transformation	  by	  Rho	  GTPases,	  and	  the	  molecule	  can	  slow	  growth	  of	  Rho	  GTPase	  transformed	  fibroblasts	  and	  breast	  cancer	  cells142.	  	  However,	  lymphocytes	  are	  also	  dependent	  on	  glutamine	  metabolism144,	  suggesting	  that	  immune	  suppression	  may	  be	  a	  side	  effect	  of	  drugs	  targeting	  glutamine	  metabolism	  for	  cancer	  therapy.	  	  	  
Targeting	  other	  metabolic	  dependencies	  in	  cancer	  cells	  Therapies	  targeting	  cancer	  metabolism	  should	  attack	  those	  metabolic	  pathways	  that	  meet	  critical	  needs	  specific	  to	  cancer	  cells.	  	  This	  approach	  is	  analogous	  to	  targeting	  nucleic	  acid	  metabolism	  with	  anti-­‐metabolites,	  but	  need	  not	  be	  limited	  to	  approaches	  that	  interfere	  with	  DNA	  replication.	  	  Many	  cancer	  cells	  rely	  on	  de	  novo	  fatty	  acid	  synthesis	  to	  generate	  new	  membranes	  for	  cell	  growth,	  and	  the	  enzymes	  involved	  directly	  in	  fatty	  acid	  synthesis	  have	  been	  suggested	  as	  cancer	  targets145,	  146.	  	  Lipids	  also	  play	  important	  signaling	  functions	  for	  cells,	  and	  chemical	  genetic	  screens	  have	  identified	  lipases	  that	  release	  fatty	  acyl	  chains	  from	  glycerol	  as	  therapeutic	  targets	  for	  some	  cancers147.	  	  It	  remains	  to	  be	  determined	  if	  targeting	  lipid	  synthesis	  to	  alter	  signal	  transduction	  or	  to	  structurally	  interfere	  with	  cell	  growth	  will	  have	  a	  better	  therapeutic	  index.	  	   NADPH	  is	  the	  major	  cofactor	  carrying	  electrons	  for	  reductive	  biosynthesis	  and	  must	  constantly	  be	  regenerated	  from	  NADP+	  to	  maintain	  reducing	  conditions	  in	  the	  cell	  and	  fuel	  biosynthetic	  reactions.	  	  Targeting	  the	  major	  sites	  of	  NADPH	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production	  in	  cancer	  cells	  could	  limit	  biosynthesis	  and	  lead	  to	  cellular	  damage	  by	  promoting	  a	  more	  oxidizing	  intracellular	  environment1.	  	  The	  pentose	  phosphate	  pathway	  is	  a	  source	  of	  NADPH	  production	  and	  may	  represent	  a	  target	  for	  cancer	  therapy148.	  	  However,	  decreased	  pentose	  phosphate	  pathway	  NADPH	  production	  is	  characteristic	  of	  patients	  with	  glucose-­‐6-­‐phosphate	  dehydrogenase	  (G6PD)-­‐deficiency,	  and	  G6PD-­‐deficiency	  has	  not	  been	  found	  to	  be	  protective	  against	  cancer149.	  	  Furthermore,	  at	  least	  some	  cancer	  types	  do	  not	  have	  a	  large	  pentose	  phosphate	  pathway	  flux150.	  	  Cells	  can	  generate	  NADPH	  via	  other	  pathways	  and	  conversion	  of	  glutamine	  to	  lactate	  via	  malic	  enzyme	  has	  been	  suggested	  both	  as	  a	  therapeutic	  target	  and	  a	  major	  source	  of	  NADPH	  in	  glioblastoma	  cells139.	  	  Whether	  other	  targets	  important	  for	  NADPH	  generation	  exist	  remains	  to	  be	  determined.	  	  
Conclusions	  and	  future	  directions	  It	  is	  clear	  that	  there	  is	  not	  a	  single	  tumor-­‐specific	  metabolism,	  but	  instead	  several	  metabolic	  programs	  exist	  to	  support	  proliferation	  of	  cancer	  cells.	  	  This	  may	  explain	  why	  current	  anti-­‐metabolite	  chemotherapies	  targeting	  DNA	  synthesis	  are	  efficacious	  in	  some	  cancers	  but	  not	  others,	  despite	  the	  need	  for	  all	  tumor	  cells	  to	  make	  nucleotides.	  	  It	  may	  also	  underlie	  why	  a	  therapeutic	  window	  exists	  for	  these	  agents	  despite	  a	  requirement	  for	  the	  same	  pathways	  in	  normal	  proliferating	  cells.	  	  A	  better	  understanding	  of	  how	  metabolism	  is	  altered	  in	  specific	  genetic	  contexts	  that	  lead	  to	  cancer	  will	  provide	  insight	  into	  which	  enzymes,	  or	  combination	  of	  enzymes,	  represent	  promising	  targets	  in	  certain	  cancers,	  and	  this	  understanding	  will	  arise	  from	  an	  analysis	  of	  metabolism	  that	  extends	  beyond	  expression	  levels	  of	  various	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enzymes	  in	  a	  pathway.	  Despite	  the	  success	  of	  targeting	  enzymes	  involved	  in	  nucleotide	  synthesis,	  efforts	  to	  target	  other	  enzymes	  and	  pathways	  in	  cellular	  metabolism	  are	  in	  their	  infancy.	  	  As	  targets	  become	  better	  defined,	  targeting	  these	  enzymes	  could	  deliver	  effective	  therapies	  that	  spare	  normal	  tissues	  and	  have	  an	  impact	  across	  a	  variety	  of	  cancers.	  	  Structural	  information	  together	  with	  a	  basic	  understanding	  of	  enzyme	  properties	  already	  exists	  for	  many	  potential	  targets	  in	  metabolism.	  	  Building	  a	  conceptual	  framework	  to	  understand	  metabolic	  regulation	  in	  cancer,	  however,	  remains	  a	  challenge	  for	  the	  development	  of	  successful	  therapies.	  	  Efforts	  to	  model	  human	  metabolism	  and	  select	  rational	  target	  combinations	  are	  ongoing151.	  	  Complementing	  these	  models	  with	  a	  more	  complete	  understanding	  of	  pathway	  biochemistry	  in	  cancer	  cells	  will	  help	  determine	  the	  best	  targets	  for	  intervention.	  	  Development	  of	  new	  methods	  to	  study	  tumor	  metabolism	  in	  vivo	  will	  be	  critical.	  	  Ultimately	  these	  efforts	  will	  determine	  if	  a	  sufficient	  therapeutic	  window	  exists	  to	  spare	  normal	  tissues	  and	  allow	  new	  drugs	  targeting	  these	  enzymes	  to	  make	  a	  difference	  in	  patients’	  lives.	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Box	  1.	  	  The	  discovery	  of	  anti-­‐folates	  as	  effective	  anti-­‐cancer	  agents.	  Targeting	  metabolism	  has	  figured	  prominently	  in	  some	  of	  the	  first	  efforts	  to	  treat	  cancer	  with	  drugs.	  	  Shortly	  after	  the	  discovery	  of	  folic	  acid	  as	  a	  nutrient	  needed	  to	  prevent	  anemia	  in	  pregnancy,	  Sidney	  Farber	  noted	  that	  administration	  of	  folic	  acid	  conjugates	  appeared	  to	  stimulate	  leukemic	  cell	  proliferation56,	  152.	  	  This	  led	  to	  one	  of	  the	  first	  examples	  of	  rational	  drug	  design	  as	  Farber,	  working	  with	  Yellapragada	  Subbarao	  and	  chemists	  at	  the	  Lederle	  Laboratories,	  developed	  the	  folate	  analog	  aminopterin	  for	  use	  in	  humans.	  	  Aminopterin	  could	  antagonize	  the	  ability	  of	  folic	  acid	  to	  stimulate	  the	  growth	  of	  bacteria,	  and	  this	  compound	  was	  the	  first	  drug	  to	  induce	  remission	  in	  children	  with	  acute	  lymphoblastic	  leukemia153.	  	  Another	  folate	  analog,	  methotrexate	  (amethopterin),	  replaced	  aminopterin	  as	  a	  cancer	  chemotherapy	  and	  produced	  the	  first	  cures	  of	  a	  solid	  tumor	  by	  chemotherapy	  (choriocarcinoma)	  in	  the	  late	  1950s154.	  	  Methotrexate	  was	  also	  the	  first	  successful	  adjuvant	  therapy	  (for	  osteosarcoma)155,	  and	  is	  still	  used	  for	  the	  management	  of	  several	  cancers	  in	  the	  clinic	  today.	  	  
Box	  2.	  	  Development	  of	  L-­‐asparaginase	  to	  treat	  ALL.	  The	  potential	  use	  of	  L-­‐asparaginase	  to	  treat	  cancer	  was	  discovered	  when	  it	  was	  noted	  that	  guinea	  pig	  serum,	  but	  not	  that	  of	  other	  animals,	  had	  an	  inhibitory	  effect	  on	  the	  proliferation	  of	  lymphoma	  cells	  in	  mice156.	  	  Guinea	  pigs	  are	  relatively	  unique	  among	  mammals	  in	  having	  serum	  aspariginase	  activity157,	  which	  was	  found	  to	  be	  responsible	  for	  the	  anti-­‐lymphoma	  effect	  in	  mice55,	  158.	  	  Asparaginase	  was	  found	  to	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be	  a	  particularly	  effective	  agent	  in	  ALL	  and	  associated	  high-­‐grade	  lymphomas,	  inducing	  remission	  as	  a	  single	  agent	  in	  greater	  than	  50%	  of	  children	  with	  the	  disease159.	  	  These	  remissions	  were	  not	  durable;	  however,	  when	  used	  as	  part	  of	  a	  combination	  chemotherapy	  regimen,	  aspariginase	  has	  contributed	  to	  a	  greater	  than	  80%	  cure	  rate	  for	  children	  with	  ALL	  and	  its	  inclusion	  in	  adult	  regimens	  has	  contributed	  to	  improved	  clinical	  outcomes160.	  
	  
Figure	  Legends	  
Figure	  1.	  Proliferating	  cell	  metabolism	  involves	  a	  shift	  in	  nutrient	  metabolism	  
towards	  biosynthesis.	  
a.	  	  Mammalian	  cells	  are	  exposed	  to	  ~5	  mM	  glucose	  and	  ~0.5	  mM	  glutamine	  in	  serum,	  and	  these	  nutrients	  are	  the	  primary	  metabolic	  fuel	  for	  cancer	  cells	  and	  many	  normal	  cells.	  	  Additional	  nutrients,	  including	  lipids	  and	  other	  amino	  acids,	  can	  also	  be	  a	  significant	  source	  of	  ATP	  and	  biosynthetic	  precursors	  for	  some	  cells.	  	  Most	  of	  the	  increased	  nutrient	  uptake	  in	  proliferating	  cells	  is	  used	  to	  support	  biosynthetic	  reactions.	  	  As	  a	  result,	  cancer	  cell	  metabolism	  involves	  many	  complex	  changes	  in	  metabolite	  flux	  beyond	  a	  switch	  in	  the	  amount	  of	  glucose	  metabolized	  by	  oxidative	  phosphorylation	  and	  aerobic	  glycolysis.	  	  Understanding	  how	  different	  cancer	  cells	  regulate	  metabolism	  to	  achieve	  a	  balance	  between	  ATP	  production	  and	  biosynthesis	  holds	  the	  key	  to	  successfully	  targeting	  enzymes	  for	  therapy.	  
b.	  	  Not	  all	  tumors	  exhibit	  the	  same	  metabolic	  phenotype.	  	  Tracer	  uptake	  studies	  in	  patients	  and	  cancer	  model	  systems	  have	  demonstrated	  that	  cancers	  show	  differential	  uptake	  of	  nutrients.	  	  This	  variety	  is	  seen	  even	  among	  different	  tumors	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arising	  from	  the	  same	  normal	  tissue.	  	  This	  heterogeneity	  should	  be	  considered	  when	  stratifying	  patients	  for	  trials	  using	  novel	  therapies	  that	  target	  cancer	  metabolism.	  
	  
Figure	  2.	  	  Some	  existing	  chemotherapies	  target	  specific	  metabolic	  enzymes.	  5-­‐fluorouracil	  (5-­‐FU)	  inhibits	  thymidylate	  synthase	  (TS),	  an	  enzyme	  required	  to	  generate	  thymidine	  for	  DNA	  synthesis.	  	  Methotrexate	  targets	  the	  dihydrofolate	  reductase	  (DHFR)	  step	  in	  folate	  metabolism.	  	  Interrupting	  folate	  metabolism	  compromises	  thymidine	  synthesis,	  but	  also	  interferes	  with	  purine	  synthesis	  and	  other	  reactions	  involving	  one-­‐carbon	  transfers.	  	  Folinic	  acid	  can	  enter	  the	  folate	  pool	  downstream	  of	  dihydrofolate	  reductase	  and	  rescue	  the	  effects	  of	  inhibiting	  this	  enzyme	  in	  some	  cells.	  	  Glycine	  can	  also	  be	  used	  to	  convert	  tetrahydrofolate	  (THF)	  to	  5,10-­‐methylene-­‐THF.	  	  
Figure	  3.	  	  Targeting	  metabolic	  enzymes	  as	  a	  strategy	  to	  block	  biosynthesis	  or	  
induce	  energy	  stress.	  A	  graphical	  representation	  of	  central	  carbon	  metabolism	  is	  presented,	  with	  some	  metabolic	  enzymes	  currently	  being	  considered	  as	  therapeutic	  targets	  for	  cancer	  marked	  with	  a	  target.	  	  Five	  drugs	  that	  influence	  metabolism	  and	  have	  been	  tested	  in	  humans	  are	  shown	  in	  red.	  	  How	  these	  enzyme	  targets	  relate	  to	  the	  synthesis	  of	  important	  macromolecules	  needed	  for	  cell	  growth	  is	  shown	  in	  yellow,	  and	  their	  relationship	  to	  mitochondrial	  ATP	  production	  is	  shown	  in	  green.	  	  Enzyme	  abbreviations	  are	  described	  in	  the	  text.	  	  Metabolic	  intermediates	  are	  abbreviated	  as	  follows:	  	  G-­‐6-­‐P,	  glucose-­‐6-­‐phosphate;	  F-­‐6-­‐P,	  fructose-­‐6-­‐phosphate;	  FBP,	  fructose-­‐
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1,6-­‐bisphosphate;	  F-­‐2,6-­‐BP,	  fructose-­‐2,6-­‐bisphosphate;	  PEP,	  phosphoenolpyruvate;	  
αKG,	  α−ketoglutarate;	  OAA,	  oxaloacetate.	  	   	  
 44	  
Table	  1:	  Strategies	  to	  target	  metabolic	  enzymes	  for	  cancer	  therapy	  
	   AGENT(s)	  
DEVELOPMENT	  
STAGE	   INDICATION	  /	  KEY	  PRECLINICAL	  FINDINGS	  






Approved	  agents	   ⋅	  Effective	  therapy	  for	  various	  cancers	  
Thymidine	  synthesis	  
⋅	  TS	  




Hydroxyurea	   Approved	  agent	   ⋅	  Effective	  therapy	  for	  leukemia	  
Nucleotide	  incorporation	  
⋅	  DNA	  polymerase	  /	  RR	  
Gemcitibine	  
Fludarabine	  




Preclinical	  Data	  Only	  
	  
⋅	  TKTL1	  allows	  non-­‐oxidative	  ribose	  production,	  and	  expression	  correlates	  with	  
poor	  prognosis	  and	  RNAi	  inhibits	  cell	  proliferation161	  
⋅	  G6PD	  is	  necessary	  for	  oxidative	  ribose	  production.	  	  High	  levels	  of	  G6PD	  seen	  in	  
some	  cancers	  and	  expression	  can	  transform	  fibroblasts148	  
Amino	  Acid	  Metabolism/Protein	  Synthesis	  
Asparagine	  availability	   L-­‐asparaginase	   Approved	  agent	   ⋅	  Effective	  therapy	  for	  leukemia	  
Arginine	  availability	   PEGylated	  
arginine	  
deiminase	   Phase	  II	  
⋅	  Arginine	  auxotrophy	  thought	  to	  be	  related	  to	  low	  arginosuccinate	  synthase	  
expression	  in	  some	  tumors62.	  
⋅	  Clinical	  efficacy	  being	  explored	  in	  hepatocellular	  carcinoma,	  melanoma,	  small	  cell	  
lung	  cancer	  and	  mesothelioma.	  
Glutamine	  availability	  
⋅	  GLS1	  
Preclinical	  Data	  Only	   ⋅	  GLS1	  converts	  glutamine	  to	  glutamate,	  likely	  is	  more	  important	  as	  a	  means	  of	  
generating	  anapleurotic	  carbon	  for	  the	  TCA	  cycle162.	  
PHGDH	  
Preclinical	  Data	  Only	  
⋅	  PHGDH	  is	  in	  a	  region	  of	  copy	  number	  gain	  that	  is	  most	  commonly	  observed	  in	  
melanoma	  and	  breast	  cancer,	  and	  cell	  lines	  with	  copy	  number	  gain	  are	  
dependent	  on	  PHGDH	  expression	  to	  proliferate163,	  164.	  
Lipid	  Synthesis	  
FAS	  
Preclinical	  Data	  Only	   ⋅	  FAS	  is	  a	  key	  enzyme	  in	  de	  novo	  lipogenesis.	  	  Growth	  of	  human	  xenograft	  tumors	  
in	  mice	  is	  inhibited	  by	  tool	  compounds165.	  
ACL	  
Preclinical	  Data	  Only	  
⋅	  ACL	  is	  necessary	  to	  export	  citrate	  from	  the	  mitochondria	  to	  the	  cytosol	  for	  de	  
novo	  lipogenesis,	  is	  important	  for	  cell	  proliferation	  and	  growth	  of	  human	  
xenograft	  tumors71,	  166.	  
ACC	  
Preclinical	  Data	  Only	   ⋅	  ACC	  is	  necessary	  for	  de	  novo	  lipogenesis	  and	  is	  required	  for	  growth	  of	  culture	  
cancer	  cells	  in	  the	  absence	  of	  exogenous	  lipids.161,	  167	  
CENTRAL	  METABOLIC	  PATHWAYS	  NECESSARY	  TO	  SUPPLY	  CARBON,	  ATP,	  AND/OR	  NAD(P)H	  
Glycolysis	  
Glucose	  transport	   Preclinical	  Data	  Only	   ⋅	  Efforts	  to	  inhibit	  glucose	  transport	  ongoing.	  
HK	   2-­‐Deoxyglucose	   Clinical	  Data	  
Preclinical	  
⋅	  Unacceptable	  toxicity	  observed	  at	  high	  doses88,	  89,	  trials	  at	  lower	  doses	  currently	  
on	  hold.	  
⋅	  Inhibition	  of	  HK	  inhibits	  proliferation,	  and	  is	  a	  rationale	  for	  selective	  HK2	  
inhibitors91,	  92.	  
PFK2FB3	  
Preclinical	  Data	  Only	   ⋅	  Controls	  key	  regulatory	  step	  in	  glycolysis,	  tool	  compounds	  inhibit	  growth	  of	  
xenograft	  tumors51.	  
PGAM	   Preclinical	  Data	  Only	   ⋅	  Identified	  in	  a	  screen	  as	  the	  target	  of	  molecule	  that	  kills	  cancer	  cells168.	  
PKM2	  
Preclinical	  Data	  Only	   ⋅	  Both	  enzyme	  activation	  and	  inhibition	  being	  explored	  (see	  text).	  
⋅	  Cancer	  cells	  expressing	  the	  PKM1	  isoform	  do	  not	  grow	  as	  xenografts99.	  
LDHA	  
Preclinical	  Data	  Only	   ⋅	  Enzyme	  responsible	  for	  lactate	  production,	  tool	  compounds	  inhibit	  xenograft	  
tumor	  growth53.	  	  
Lactate	  excretion	  
⋅	  MCT4	   Preclinical	  Data	  Only	  
⋅	  Lactate	  is	  excreted	  from	  cells	  via	  monocarboxylate	  transporters.	  
⋅	  MCT4	  is	  the	  transporter	  used	  by	  some	  cancer	  cells111,	  and	  small	  molecule	  MCT	  
inhibitors	  can	  block	  cell	  proliferation114.	  	  
TCA	  cycle	  /	  mitochondrial	  metabolism	  
PDK	   Dichloroacetate	   Phase	  II	   ⋅	  Compound	  available	  in	  the	  clinic	  for	  treating	  lactic	  acidosis	  related	  to	  inborn	  
errors	  of	  metabolism.	  	  Can	  modulate	  mitochondrial	  metabolism	  in	  human	  
gliomas,	  and	  clinical	  efficacy	  being	  studied81.	  
IDH1	  
IDH2	  
Preclinical	  Data	  Only	  
⋅	  2-­‐hydroxyglutarate	  production	  by	  mutant	  enzymes	  linked	  to	  cancer	  
pathogenesis128,	  129,	  130.	  
⋅	  Decreased	  wildtype	  enzyme	  using	  RNAi	  can	  impair	  proliferation	  of	  wildtype	  IDH	  
cancer	  cells129.	  
Malic	  Enzyme	   Preclinical	  Data	  Only	   ⋅	  Key	  enzyme	  involved	  in	  NADPH	  production139,1.	   	  
Mitochondrial	  Complex	  I	   Metformin	   Approved	  Agent	   ⋅	  Improved	  survival	  in	  diabetics	  with	  cancer24,	  and	  increased	  response	  rate	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(non-­‐cancer)	   observed	  in	  breast	  cancer	  patients	  taking	  metformin30.	  




Preclinical	  Data	  Only	  
⋅	  GLS1	  converts	  glutamine	  to	  glutamate,	  and	  GDH	  converts	  glutamate	  to	  αKG	  as	  a	  
source	  of	  anapleurotic	  carbon	  for	  the	  TCA	  cycle162.	  
⋅	  GDH	  required	  for	  proliferation	  of	  some	  cells169.	  
⋅	  Inhibition	  of	  GLS1	  impairs	  proliferation	  of	  some	  cells142.	  	  
PC	  
Preclinical	  Data	  Only	  
⋅	  PC	  provides	  an	  alternative	  route	  to	  replenish	  the	  TCA	  cycle	  when	  GLS	  is	  inhibited,	  
suggesting	  PC	  inhibition	  could	  synergize	  with	  GLS	  inhibition	  in	  glutamine	  
addicted	  cells170.	  
Fatty	  Acid	  Metabolism	  
MAGL	   Preclinical	  Data	  Only	   ⋅	  MAGL	  inhibition	  impairs	  the	  growth	  of	  xenograft	  tumors147.	  
CPT1C	   Preclinical	  Data	  Only	   ⋅	  Tool	  compounds	  inhibit	  growth	  of	  xenograft	  tumors171.	  
NAD	  Metabolism	   	   	  
NAMPT	   Various	   Phase	  II	   ⋅	  FK866	  had	  a	  dose	  limiting	  toxicity	  of	  thrombocytopenia	  in	  phase	  I	  trials123,	  and	  
NAMPT	  inhibitors	  are	  being	  considered	  for	  further	  development	  as	  a	  cancer	  
therapy119,	  124.	  Abbreviations:	  DHFR,	  dihydrofolate	  reductase;	  TS,	  thymidylate	  synthase;	  RR,	  ribonucleotide	  reductase;	  TKTL1,	  transketolase-­‐like	  protein	  1;	  G6PD,	  glucose-­‐6-­‐phosphate	  dehydrogenase;	  GLS1,	  glutaminase	  1;	  PHGDH,	  phosphoglycerate	  dehydrogenase;	  FAS,	  fatty	  acid	  synthase;	  ACL,	  ATP-­‐citrate	  lyase;	  ACC,	  acetyl-­‐coA	  carboxylase;	  HK,	  hexokinase;	  PFK2FB3,	  phosphofructokinase	  isoform	  FB3;	  PGAM1,	  phosphoglycerate	  mutase	  isoform	  1;	  PKM2,	  pyruvate	  kinase	  isoform	  M2;	  LDHA,	  lactate	  dehydrogenase	  A;	  MCT4,	  monocarboxylate	  transporter	  4;	  PDK,	  pyruvate	  dehydrogenase	  kinase;	  IDH,	  isocitrate	  dehydrogenase;	  GDH,	  glutamate	  dehydrogenase;	  PC,	  pyruvate	  carboxylase;	  MAGL,	  monoacylglycerol	  lipase;	  CPT1C,	  carnitine	  palmitoyl	  transferase	  1C;	  NAMPT,	  nicotinamide	  phosphoribosyltransferase.	  



